APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Therapeutic Antibodies and Proteins

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant Therapeutic Antibodies and Proteins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025190 pages

Choose your research edition.

Industry ResearchRecombinant Therapeutic Antibodies and Proteins Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Therapeutic Antibodies and Proteins Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Recombinant Therapeutic Antibodies and Proteins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Therapeutic Antibodies and Proteins Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Therapeutic Antibodies and Proteins Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Recombinant Therapeutic Antibodies and Proteins market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Recombinant Therapeutic Antibodies and Proteins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Therapeutic Antibodies and Proteins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Therapeutic Antibodies and Proteins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant Therapeutic Antibodies and Proteins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Therapeutic Antibodies and Proteins include Biogen, Novo Nordisk, Amgen, Pfizer, Eli Lilly, Roche, Merck, Johnson and Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Recombinant Therapeutic Antibodies and Proteins market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Therapeutic Antibodies and Proteins and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Therapeutic Antibodies and Proteins revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Recombinant Therapeutic Antibodies and Proteins market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Therapeutic Antibodies and Proteins Segment by Company

Biogen

Novo Nordisk

Amgen

Pfizer

Eli Lilly

Roche

Merck

Johnson and Johnson

Sanofi

Abbott

Recombinant Therapeutic Antibodies and Proteins Segment by Type

Plasma Protein

Fusion Proteins

Coagulation Factors

Enzyme

Hormones

Monoclonal Antibodies

Others

Recombinant Therapeutic Antibodies and Proteins Segment by Application

Enzyme

Monoclonal Antibodies

Hormones

Coagulation Factors

Fusion Proteins

Plasma Protein

Others

Recombinant Therapeutic Antibodies and Proteins Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Therapeutic Antibodies and Proteins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Therapeutic Antibodies and Proteins and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Therapeutic Antibodies and Proteins.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Recombinant Therapeutic Antibodies and Proteins in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Therapeutic Antibodies and Proteins industry.

Chapter 3: Detailed analysis of Recombinant Therapeutic Antibodies and Proteins companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Therapeutic Antibodies and Proteinsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Plasma Protein Table 3. Key Players of Fusion Proteins Table 4. Key Players of Coagulation Factors Table 3. Key Players of Enzyme Table 4. Key Players of Hormones Table 5. Key Players of Monoclonal Antibodies Table 6. Key Players of Others Table 7. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 8. Key Players of Enzyme Table 9. Key Players of Monoclonal Antibodies Table 10. Key Players of Hormones Table 11. Key Players of Coagulation Factors Table 12. Key Players of Fusion Proteins Table 13. Key Players of Plasma Protein Table 14. Key Players of Others Table 15. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Region (2021-2026) Table 18. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Region (2027-2032) Table 20. Recombinant Therapeutic Antibodies and Proteins Industry Trends Table 21. Recombinant Therapeutic Antibodies and Proteins Industry Drivers Table 22. Recombinant Therapeutic Antibodies and Proteins Industry Opportunities and Challenges Table 23. Recombinant Therapeutic Antibodies and Proteins Industry Restraints Table 24. Global Recombinant Therapeutic Antibodies and Proteins Revenue by Company (US$ Million) & (2021-2026) Table 25. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Company (2021-2026) Table 26. Global Recombinant Therapeutic Antibodies and Proteins Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 27. Global Recombinant Therapeutic Antibodies and Proteins Key Company Head Office and Area Served Table 28. Global Recombinant Therapeutic Antibodies and Proteins Company, Product Type & Application Table 29. Global Recombinant Therapeutic Antibodies and Proteins Company Establishment Date Table 30. Global Company Market Concentration Ratio (CR5 and HHI) Table 31. Global Recombinant Therapeutic Antibodies and Proteins by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 32. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026) & (US$ Million) Table 34. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032) & (US$ Million) Table 35. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2021-2026) Table 36. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2027-2032) Table 37. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026) & (US$ Million) Table 39. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032) & (US$ Million) Table 40. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Application (2021-2026) Table 41. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Application (2027-2032) Table 42. Biogen Company Information Table 43. Biogen Business Overview Table 44. Biogen Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Biogen Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 46. Biogen Recent Development Table 47. Novo Nordisk Company Information Table 48. Novo Nordisk Business Overview Table 49. Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 51. Novo Nordisk Recent Development Table 52. Amgen Company Information Table 53. Amgen Business Overview Table 54. Amgen Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Amgen Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 56. Amgen Recent Development Table 57. Pfizer Company Information Table 58. Pfizer Business Overview Table 59. Pfizer Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Pfizer Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 61. Pfizer Recent Development Table 62. Eli Lilly Company Information Table 63. Eli Lilly Business Overview Table 64. Eli Lilly Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Eli Lilly Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 66. Eli Lilly Recent Development Table 67. Roche Company Information Table 68. Roche Business Overview Table 69. Roche Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Roche Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 71. Roche Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Merck Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 76. Merck Recent Development Table 77. Johnson and Johnson Company Information Table 78. Johnson and Johnson Business Overview Table 79. Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 81. Johnson and Johnson Recent Development Table 82. Sanofi Company Information Table 83. Sanofi Business Overview Table 84. Sanofi Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Sanofi Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 86. Sanofi Recent Development Table 87. Abbott Company Information Table 88. Abbott Business Overview Table 89. Abbott Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Abbott Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 91. Abbott Recent Development Table 92. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026) & (US$ Million) Table 93. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032) & (US$ Million) Table 94. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026) & (US$ Million) Table 95. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032) & (US$ Million) Table 96. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021-2026) Table 98. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2027-2032) Table 99. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026) & (US$ Million) Table 100. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032) & (US$ Million) Table 101. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026) & (US$ Million) Table 102. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032) & (US$ Million) Table 103. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021-2026) Table 105. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2027-2032) Table 106. China Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026) & (US$ Million) Table 107. China Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032) & (US$ Million) Table 108. China Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026) & (US$ Million) Table 109. China Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032) & (US$ Million) Table 110. Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026) & (US$ Million) Table 111. Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032) & (US$ Million) Table 112. Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026) & (US$ Million) Table 113. Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032) & (US$ Million) Table 114. Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021-2026) Table 116. Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2027-2032) Table 117. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026) & (US$ Million) Table 118. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032) & (US$ Million) Table 119. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026) & (US$ Million) Table 120. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032) & (US$ Million) Table 121. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021-2026) Table 123. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Recombinant Therapeutic Antibodies and Proteins Product Image Figure 2. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Type: 2025 VS 2032 Figure 4. Plasma Protein Image Figure 5. Fusion Proteins Image Figure 6. Coagulation Factors Image Figure 7. Enzyme Image Figure 8. Hormones Image Figure 9. Monoclonal Antibodies Image Figure 10. Others Image Figure 11. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 12. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Application: 2025 VS 2032 Figure 13. Enzyme Image Figure 14. Monoclonal Antibodies Image Figure 15. Hormones Image Figure 16. Coagulation Factors Image Figure 17. Fusion Proteins Image Figure 18. Plasma Protein Image Figure 19. Others Image Figure 20. Global Recombinant Therapeutic Antibodies and Proteins Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 21. Global Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 22. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Region: 2025 VS 2032 Figure 23. Years Considered Figure 24. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Players in 2025 Figure 25. Global Top 5 and 10 Recombinant Therapeutic Antibodies and Proteins Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2021-2032) Figure 29. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Application (2021-2032) Figure 31. North America Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 32. North America Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032) Figure 33. North America Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032) Figure 34. North America Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2021-2032) Figure 35. United States Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 36. Canada Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 37. Mexico Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 38. Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 39. Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032) Figure 40. Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032) Figure 41. Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2021-2032) Figure 42. Germany Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 43. France Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 44. U.K. Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 45. Italy Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 46. Russia Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 47. Nordic Countries Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 48. China Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 49. China Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032) Figure 50. China Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032) Figure 51. Asia Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 52. Asia Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032) Figure 53. Asia Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032) Figure 54. Asia Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2021-2032) Figure 55. Japan Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 56. South Korea Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 57. Taiwan Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 58. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 59. India Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 60. Australia Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 61. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 62. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032) Figure 63. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032) Figure 64. South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2021-2032) Figure 65. Brazil Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 66. South Africa Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 67. Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 68. Turkey Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 69. Argentina Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 70. UAE Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 71. Egypt Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 72. Chile Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Plasma Protein
  • Fusion Proteins
  • Coagulation Factors
  • Enzyme
  • Hormones
  • Monoclonal Antibodies
  • Others
Applications
  • Enzyme
  • Monoclonal Antibodies
  • Hormones
  • Coagulation Factors
  • Fusion Proteins
  • Plasma Protein
  • Others
Companies covered
  • Biogen
  • Novo Nordisk
  • Amgen
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck
  • Johnson and Johnson
  • Sanofi
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Plasma Protein
  5. 1.2.3 Fusion Proteins
  6. 1.2.4 Coagulation Factors
  7. 1.2.5 Enzyme
  8. 1.2.6 Hormones
  9. 1.2.7 Monoclonal Antibodies
  10. 1.2.8 Others
  11. 1.3 Market Analysis by Application
  12. 1.3.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  13. 1.3.2 Enzyme
  14. 1.3.3 Monoclonal Antibodies
  15. 1.3.4 Hormones
  16. 1.3.5 Coagulation Factors
  17. 1.3.6 Fusion Proteins
  18. 1.3.7 Plasma Protein
  19. 1.3.8 Others
  20. 1.4 Global Market Growth Prospects
  21. 1.5 Global Recombinant Therapeutic Antibodies and Proteins Growth Trends by Region
  22. 1.5.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Region: 2021 VS 2025 VS 2032
  23. 1.5.2 Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2021-2026)
  24. 1.5.3 Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2027-2032)
  25. 1.6 Assumptions and Limitations
  26. 1.7 Study Goals and Objectives
  27. 1.8 Years Considered
2 Global Recombinant Therapeutic Antibodies and Proteins Market Dynamics
  1. 2.1 Recombinant Therapeutic Antibodies and Proteins Industry Trends
  2. 2.2 Recombinant Therapeutic Antibodies and Proteins Industry Drivers
  3. 2.3 Recombinant Therapeutic Antibodies and Proteins Industry Opportunities and Challenges
  4. 2.4 Recombinant Therapeutic Antibodies and Proteins Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Recombinant Therapeutic Antibodies and Proteins Revenue by Company (2021-2026)
  2. 3.2 Global Recombinant Therapeutic Antibodies and Proteins Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Recombinant Therapeutic Antibodies and Proteins Key Company Head office and Area Served
  4. 3.4 Global Recombinant Therapeutic Antibodies and Proteins Company, Product Type & Application
  5. 3.5 Global Recombinant Therapeutic Antibodies and Proteins Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Recombinant Therapeutic Antibodies and Proteins Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Recombinant Therapeutic Antibodies and Proteins Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Recombinant Therapeutic Antibodies and Proteins Tier 1, Tier 2, and Tier 3
4 Recombinant Therapeutic Antibodies and Proteins Market by Type
  1. 4.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2032)
  3. 4.3 Global Recombinant Therapeutic Antibodies and Proteins Market Size Share by Type (2021-2032)
5 Recombinant Therapeutic Antibodies and Proteins Market by Application
  1. 5.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2032)
  3. 5.3 Global Recombinant Therapeutic Antibodies and Proteins Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Biogen
  2. 6.1.1 Biogen Company Information
  3. 6.1.2 Biogen Business Overview
  4. 6.1.3 Biogen Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Biogen Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  6. 6.1.5 Biogen Recent Developments
  7. 6.2 Novo Nordisk
  8. 6.2.1 Novo Nordisk Company Information
  9. 6.2.2 Novo Nordisk Business Overview
  10. 6.2.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  12. 6.2.5 Novo Nordisk Recent Developments
  13. 6.3 Amgen
  14. 6.3.1 Amgen Company Information
  15. 6.3.2 Amgen Business Overview
  16. 6.3.3 Amgen Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Amgen Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  18. 6.3.5 Amgen Recent Developments
  19. 6.4 Pfizer
  20. 6.4.1 Pfizer Company Information
  21. 6.4.2 Pfizer Business Overview
  22. 6.4.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Pfizer Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  24. 6.4.5 Pfizer Recent Developments
  25. 6.5 Eli Lilly
  26. 6.5.1 Eli Lilly Company Information
  27. 6.5.2 Eli Lilly Business Overview
  28. 6.5.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  30. 6.5.5 Eli Lilly Recent Developments
  31. 6.6 Roche
  32. 6.6.1 Roche Company Information
  33. 6.6.2 Roche Business Overview
  34. 6.6.3 Roche Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Roche Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  36. 6.6.5 Roche Recent Developments
  37. 6.7 Merck
  38. 6.7.1 Merck Company Information
  39. 6.7.2 Merck Business Overview
  40. 6.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Merck Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  42. 6.7.5 Merck Recent Developments
  43. 6.8 Johnson and Johnson
  44. 6.8.1 Johnson and Johnson Company Information
  45. 6.8.2 Johnson and Johnson Business Overview
  46. 6.8.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  48. 6.8.5 Johnson and Johnson Recent Developments
  49. 6.9 Sanofi
  50. 6.9.1 Sanofi Company Information
  51. 6.9.2 Sanofi Business Overview
  52. 6.9.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Sanofi Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  54. 6.9.5 Sanofi Recent Developments
  55. 6.10 Abbott
  56. 6.10.1 Abbott Company Information
  57. 6.10.2 Abbott Business Overview
  58. 6.10.3 Abbott Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Abbott Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  60. 6.10.5 Abbott Recent Developments
7 North America
  1. 7.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032)
  2. 7.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type
  3. 7.2.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026)
  4. 7.2.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032)
  5. 7.2.3 North America Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032)
  6. 7.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application
  7. 7.3.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026)
  8. 7.3.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032)
  9. 7.3.3 North America Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032)
  10. 7.4 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country
  11. 7.4.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021-2026)
  13. 7.4.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2027-2032)
  14. 7.4.4 North America Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032)
  2. 8.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type
  3. 8.2.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026)
  4. 8.2.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032)
  5. 8.2.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032)
  6. 8.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application
  7. 8.3.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026)
  8. 8.3.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032)
  9. 8.3.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032)
  10. 8.4 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country
  11. 8.4.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021-2026)
  13. 8.4.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2027-2032)
  14. 8.4.4 Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032)
  2. 9.2 China Recombinant Therapeutic Antibodies and Proteins Market Size by Type
  3. 9.2.1 China Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026)
  4. 9.2.2 China Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032)
  5. 9.2.3 China Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032)
  6. 9.3 China Recombinant Therapeutic Antibodies and Proteins Market Size by Application
  7. 9.3.1 China Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026)
  8. 9.3.2 China Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032)
  9. 9.3.3 China Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032)
  2. 10.2 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Type
  3. 10.2.1 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026)
  4. 10.2.2 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032)
  5. 10.2.3 Asia Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032)
  6. 10.3 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Application
  7. 10.3.1 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026)
  8. 10.3.2 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032)
  9. 10.3.3 Asia Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032)
  10. 10.4 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Country
  11. 10.4.1 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021-2026)
  13. 10.4.3 Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2027-2032)
  14. 10.4.4 Asia Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst